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Defining the human copper proteome and
analysis of its expression variation in cancers†
S. Blockhuys,a E. Celauro,a C. Hildesjo¨,bc A. Feizi,a O. Stål,b J. C. Fierro-Gonza´lez*a
and P. Wittung-Stafshede*a
Copper (Cu) is essential for living organisms, and acts as a cofactor in many metabolic enzymes. To avoid
the toxicity of free Cu, organisms have specific transport systems that ‘chaperone’ the metal to targets.
Cancer progression is associated with increased cellular Cu concentrations, whereby proliferative
immortality, angiogenesis and metastasis are cancer hallmarks with defined requirements for Cu. The aim of
this study is to gather all known Cu-binding proteins and reveal their putative involvement in cancers using
the available database resources of RNA transcript levels. Using the Uniprot.org database along with manual
curation, we identified a total of 54 Cu-binding proteins (named the human Cu proteome). Next, we
retrieved RNA expression levels in cancer versus normal tissues from the TCGA database for the human Cu
proteome in 18 cancer types, and noted an intricate pattern of up- and downregulation of the genes in
diﬀerent cancers. Hierarchical clustering in combination with bioinformatics and functional genomics
analyses allowed for the prediction of cancer-related Cu-binding proteins; these were specifically inspected
for the breast cancer data. Finally, for the Cu chaperone ATOX1, which is the only Cu-binding protein
proposed to have transcription factor activities, we validated its predicted over-expression in patient breast
cancer tissue at the protein level. This collection of Cu-binding proteins, with RNA expression patterns in
diﬀerent cancers, will serve as an excellent resource for mechanistic–molecular studies of Cu-dependent
processes in cancer.
Significance to metallomics
Copper is an essential metal ion that facilitates many biological functions. This work adopts a global approach and first summarizes all known human copper-
binding proteins and then investigates their putative importance in cancer using a recognized database of RNA expression information for an extended set of cancer
types. The expanding functional repertoire of metalloproteins justifies further studies of metalloproteins in order to address non-traditional functions in cell signaling
and diseases, such as cancer. Here, we provide new information that may be used by others to explore cancer mechanisms related to copper-ion dependence.
Introduction
Cu is essential to living organisms and acts as a cofactor in key
enzymes, but the redox properties that allow the metal to impart
activities to proteins also imply the potential for toxicity.1 To
minimize the toxic eﬀects and strictly regulate the temporal and
spatial distributions of Cu, organisms have evolved elaborate
systems for the uptake, intracellular transport, protein loading
and storage of Cu. In human cells, after internalization of Cu by
the Cu importer CTR1,2 Cu is distributed in the cytoplasm via at
least three pathways:3 in the secretory path, the cytoplasmic Cu
chaperone ATOX1 delivers Cu to the Cu-transporting P1B-type
ATPases ATP7A and ATP7B, also called Wilson and Menkes
disease proteins, in the trans-Golgi network. Once transferred
to ATP7A/B, Cu is channeled to the lumen and, upon ATP
hydrolysis, loaded onto many target Cu-dependent enzymes,
e.g., ceruloplasmin (CP) and lysyl oxidase (LOX).4 CP constitutes
the major Cu transporter in blood plasma, where it acts as a
ferroxidase, oxidizing iron, and delivering Cu to other cells.5–8
LOX is also a secreted Cu-dependent enzyme and crosslinks
extracellular matrix proteins. In addition to the secretory path-
way, there are two other paths for Cu transport in the cytoplasm.
In one, the Cu chaperone for superoxide dismutase 1 (CCS)
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directs Cu to cytoplasmic Cu/Zn superoxide dismutase 1 (SOD1);
in the other, Cu is transported to mitochondria by COX17, and
with help from additional proteins (i.e., SCOs and COX11), Cu is
incorporated into cytochrome c oxidase (COX1 and COX2).
Since Cu is a key component in many essential enzymes,1,9,10 it
is not surprising that Cu is required for at least three characteristic
phenomena involved in cancer progression: proliferative
immortality, angiogenesis, and metastasis.11,12 In support of
increased Cu demand, cancer tissue and cancer patients’ serum
have increased Cu levels, whereas serum levels of other metals
(i.e., iron, zinc) are often lower than normal.11 Cancer progres-
sion involves uncontrolled growth of cells, followed by cancer
cell invasion, dissemination and secondary tumor formation at
local and distant sites. For a tumor to grow larger than a few
mm, angiogenesis is needed. Cu influences several molecular
pathways that induce a pro-angiogenic response,13 including
direct binding to, and promoting the expression of, angiogenic
factors.14,15 Cu also influences the ability of cancerous cells to
metastasize through activation of metabolic and proliferative
enzymes.11 For example, LOX is secreted by cancer cells to
create a pro-metastatic niche.16,17
Recent unprecedented findings suggest that ATOX1 has
transcription factor activities connected to cancer progression.18
ATOX1 acts as a Cu-dependent transcription factor19 that promotes
the expression of cyclin D1, a key protein involved in the cell
cycle and cell proliferation,20 and the Cu-dependent enzyme
SOD3, a major extracellular antioxidant protein and a protectant
against hypertension.21,22 ATOX1 also promotes inflammatory
neovascularization by acting as a Cu-dependent transcription
factor for NADPH oxidase,23 and is essential for platelet-derived
growth factor-induced Cu-dependent cell migration, thus potentially
regulating malignant angiogenesis and vascular remodeling.24 In
some analogy with ATOX1, CCS transports Cu to the nucleus and
regulates the formation of the hypoxia-inducible factor 1 (HIF-1)
transcriptional complex, which in turn promotes the expression of
the vascular endothelial growth factor (VEGF) and, thereby, tumor
growth.25 Our research group recently confirmed the presence of
ATOX1 in the nucleus of mammalian cells, but found no binding to
the proposed DNA promoter sequence in vitro.26 Nonetheless, from
an extensive yeast two hybrid screening, using ATOX1 as a bait,
several new human protein partners were detected:27 interestingly,
among the confident hits, several proteins are related to cancer
(e.g., CPEB4, DNMT1, and PPM1A that regulate RNA transcription,
DNA methylation, and phosphorylation, respectively28–31).
To get a global view, we established here the human copper
proteome (i.e., the collection of all identified human Cu-binding
proteins) and then analyzed their RNA transcript level changes
in diﬀerent cancer tissues using information taken from the
publicly-available TCGA database. The Cancer Genome Atlas, or
TCGA, is a collaboration between the National Cancer Institute
(NCI) and the National Human Genome Research Institute
(NHGRI) that has generated comprehensive, multi-dimensional
maps of genomic changes in many diﬀerent cancers. It was
recently updated to include RNA transcript levels for 25 diﬀerent
cancer types (GDC data portal accessed on 22 Aug 2016). Based
on functional genomics and bioinformatics analysis of the
extracted expression level data, we identified Cu-binding proteins
that appear important in cancer and, finally, in a proof-of-principle
experiment, we confirmed the upregulation of the ATOX1 protein
in patient breast cancer tissue.
Methods
Data mining
Cu-binding proteins were identified using Uniprot.org, literature
review, and manual curation. As a first screening, genes were
extracted from Uniprot.org using the search terms ‘human +
copper’. We then manually checked each gene in Uniprot and
selected only the ones defined as Cu-binding or Cu-transport.
Although not defined as Cu-binding in Uniprot, we added SPARC,
MEMO1 and MAP2K1 as Cu-binding proteins, based on literature
reports.32–34 This resulted in a total of 54 proteins that can
be classified as Cu-binding. Subcellular localization of the 54
Cu-binding proteins was retrieved from the section ‘Localiza-
tion’ in Genecards.org. Protein function was extracted from
Uniprot.org and literature.
RNA-seq data analysis
The normalized gene expression quantification data for 54 copper-
binding genes and 18 tumor types were downloaded from the GDC
data portal. The values are upper quartile normalized FPKM count
estimates for sequence reads mapping to the genes. The log2-fold
change (lfc = log 2(tumor/normal)) and p-values (t-test) were
calculated from the normalized expression data for each gene
and tumor type. To visualize the similarity in the gene expression
patterns, a heat map was created with R version 3.3.0 (http://
www.r-project.org) using the heat map.2 function in R’s ‘gplot’
package (version 3.0.1). The genes and tumors were classified
based on the Pearson correlation coeﬃcients as a similarity
measure in gene expression and Ward2’s hierarchical clustering
method. The classifications for interpretation of the strengths of
the Pearson’s correlations were implemented according to
Cohen.35 The proteo-genomics heat map in Fig. 4 is based on
data presented by Mertins et al.36 following PAM50-defined
molecular subtypes.37
Cluster and GO (gene ontology) term enrichment analysis
The Cytoscape software (http://www.cytoscape.org)38 was used
together with GeneMania App39 to generate interaction networks
for all clusters of Cu-binding proteins identified in the heat map.
The global parameters were: (i) data source, selected considering
the known co-expression, and physical (protein–protein) and
genetic interactions; (ii) maximum resultant genes, set to double
the size of each cluster; and (iii) an automatic weighting method
to assign values to each node. Genes in query get the maximum
node size in the Cytoscape graph, whereby the size of a related
gene is inversely proportional to the rank of that gene in the list,
sorted using the score assigned by GeneMANIA. In a separate
(top-down) approach, we analyzed the overall GO term enrich-
ment by calculation of the weighted average log2-fold change of
the expression of all genes in cancer, with a cut-off value of 0.6,
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followed by ranking of the genes by the absolute value of their
log 2-fold change (i.e., over- and underrepresented genes above
the cut-off taken together). Then, we used this ranked and non-
redundant list of gene identifiers as input for the GO enrichment
analysis tool Gorilla (http://cbl-gorilla.cs.technion.ac.il/),40 with the
p-value threshold set to 103 and retrieving the most represented
biological processes. The resulting table, ranked by the FDR q-value
(i.e., a correction of the above p-value using the Benjamini and
Hochberg method), was fed to the ReviGO platform (http://revigo.
irb.hr/)41 to visualize a semantic similarity-based scatterplot. The
circles’ color represents the log10 p-value.
Patient material
The breast cancer material consists of tissue microarrays (TMAs)
of biopsies originating from a cohort of post-menopausal breast
cancer patients enrolled in a randomized clinical trial between
1976 and 1990. Briefly, breast cancer patients with a tumor
diameter r30 mm and no lymph node involvement were
included. The patients were randomized to receive tamoxifen
for two years or no endocrine treatment. Nottingham histo-
logical grade and immunohistochemical staining of ER, PR
and HER2 were performed retrospectively according to standar-
dized methods used in clinical routine.42 Retrospective studies
of biomarkers were approved by the regional ethical review
board at the Karolinska Institute, Stockholm, Sweden (KI 97-
451, with amendment 030201). The four molecular breast cancer
subtypes were defined as follows: luminal A, ER+/PR+/HER2/
low mitotic count; luminal B, ER+/(high mitotic count and/or
PR and/or HER2+); HER2-subtype (ER/HER2+); and triple
negative breast cancer (TNBC; ER, PR and HER2).
Immunohistochemical (IHC) staining of ATOX1 in breast tissue
The paraﬃn embedded sections were incubated at 65 1C for
2 h, followed by deparaﬃnization in Aqua de Par 10X Ancillary
reagent (Biocare Medical, Concord California) for 20 min. The
sections were then subjected to treatment with Borg Decloaker
RTU antigen retrieval solution (Biocare Medical, Concord California)
for heat induced epitope retrieval (HIER) using a Decloaking
Chamber NxGen pressure cooker (Biocare Medical, Concord
California) programed in a temperature cycle to reach a maximum
of 110 1C for 5 min. After allowing cooling down, the slides were
rinsed in tap water prior to washing in TBS (Tris-buﬀered saline).
After blocking endogenous peroxidase by incubation in Peroxi-
dazed 1 (Biocare Medical, Concord California) for 5 min, the slides
were washed in TBS and incubated with the mouse monoclonal
anti-ATOX1 primary antibody (ab54865, Abcam) for 30min at room
temperature (RT) followed by incubation with the secondary anti-
body MACH4 Universal HRP (horseradish peroxidase)-Probe and
the tertiary antibody MACH4 Universal HRP-Polymer (Biocare
Medical, Concord California) for 10 min each at RT. After HRP
detection, the tissue section was rinsed in TBS. For visualization,
one drop (32 ml) of DAB chromogen per 1.0 ml of DAB substrate
buﬀer (Biocare Medical, Concord California) was applied to the
tissue sections followed by incubation for 5 min at RT. After rinsing
in deionized water, the sections were counterstained with Mayer’s
haematoxylin staining solution (Histolab Products AB, Go¨teborg
Sweden) and mounted with Pertex mounting media (Histolab
Products AB, Go¨teborg Sweden). The immunostaining was scored
by two independent observers based on the intensity in the
epithelial cells without knowledge of clinicopathological and bio-
logical information. The staining intensity was scored according to
the following criteria: negative (no brown), weak (light brown),
moderate (brown), and strong (dark brown) staining. In total, 67
breast cancer tissue samples were reliably analyzed along with four
normal breast tissue samples. (Due to the limited sample number,
a statistical comparison between the scoring data for the subtypes
and the control tissue, calculated using Fisher’s exact test, resulted
in no statistical significance.) Notably, matching samples of normal
and cancerous breast tissue from the same patient are desired to
obtain higher statistical power (not available for this dataset).
Results and discussion
I. The human Cu proteome
To gather all human proteins known to bind Cu, we used
Uniprot.org as a source and identified all proteins classified
as Cu binding or Cu transporting (Table S1, ESI† with proposed
functions of each protein, if reported). To the list, we added
SPARC, MEMO1 and MAP2K1 as Cu-binding proteins, based on
literature reports,32–34 although they are not yet described as
such in UniProt. Next, we used stringent criteria in Genecards.
org with assignment by both UniProtKB and COMPARTMENTS
(confidence levels 4 or 5) to separate the proteins according to
their subcellular localizations. Subcellular localizations for 46
of the 54 identified Cu-binding proteins were indicated follow-
ing these stringent criteria. ATOX1, MEMO1, MT3, LTF and
S100A5 were localized according to less stringent criteria with
assignment by COMPARTMENTS (confidence level 4 or 5) only,
and CUTA and MT4 according to even less stringent criteria
with assignment by COMPARTMENTS (confidence level 2).
MOXD2P was the only Cu protein that remained unassigned.
As MOXD2P is a pseudogene of MOXD1, we speculated that it
occupies the same subcellular site as MOXD1, i.e., the endo-
plasmic reticulum (Fig. 1 and Table S1, ESI†).
The list of 54 Cu-binding proteins (Fig. 1 and Table S1, ESI†)
corresponds to less than 0.5% of the whole proteome (which
consists of at least 10 000 diﬀerent proteins). This fraction is
expected based on earlier estimates using a bioinformatics
approach.43 There are two important points: first, there may
be more proteins to be discovered as Cu-binding proteins.
Thus, the list will grow with time. Second, some of the proteins
defined as Cu-binding proteins may not use Cu for their
function. For example, the three amyloidogenic proteins SNCA
(a-synuclein), APP (amyloid b precursor protein) and PRNP
(prion protein) are reported to bind Cu, but neither the role
of Cu nor the exact functions are determined for these
proteins.44–47
We found that human cells have 12 proteins classified as Cu
transporters. For import there are SLC31A1 and SLC31A2 (CTR1
and CTR2), for cytoplasmic transport there are CCS for Cu
delivery to SOD1, ATOX1 for Cu delivery to ATP7A/B in the
Metallomics Paper
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Golgi, and then COX11, COX17, SCO1, and SCO2 that provide Cu to
COX1 and COX2 in the mitochondria. COMMD1 is an enigmatic
protein that may be involved in the regulation of exocytosis of
Cu-loaded vesicles,48,49 perhaps via modulation of ATP7B protein
stability.50 Whether CUTC is truly a Cu transporter, as reported
here, or a Cu-dependent enzyme instead, is an open question.51
We observed that about half of the identified Cu-binding
proteins are Cu-dependent enzymes (Fig. 1 and Table S1, ESI†).
Many are found extracellular and in the plasma membrane, but
also in all (but Golgi) intracellular compartments. In addition
to many well-characterized Cu-dependent enzymes, PARK7 is
classified as a Cu-dependent enzyme. It is a peptidase that may
also function as a sensor for oxidative stress and, notably,
mutations in this gene are the cause of early-onset Parkinson’s
disease.52,53 In addition to Cu homeostasis and enzymatic activity,
we functionally classified the remaining 15 proteins in the Cu
proteome as ‘other’ which corresponds to either non-enzymatic or
unknown functions (Table S1, ESI†). Interesting proteins in this
group are four S100 proteins, typically EF-hand calcium-binding
proteins, which have Cu-binding sites and Cu-dependent
functions.54 Notably, none (but ATOX1, see Introduction) of
the identified Cu-binding proteins are transcription factors.
In addition to LOX (collagen cross-linking) and ATOX1/CCS
(putative transcription factor roles), only a few other proteins in the
Cu proteome have yet been shown to play roles in cancer. MAP2K1
(MEK1) is a kinase involved in the mitogen-activated protein kinase
signaling pathway, and directly related to tumor growth,18 invasion
and metastasis.55,56 MEMO1 is a Cu-dependent redox enzyme that
facilitates tumor cell migration and in vivo metastasis57 via, for
example, production of reactive oxygen species, regulation of
transcriptional pathways related to the epithelial to mesenchymal
transition,58 and interaction with the RhoA–mDia1 signaling
complex.59 SPARC, a collagen-binding glycoprotein, plays a role
in tumor invasion and metastasis via modulation of cell–cell and
cell–matrix interactions.32,33 Interestingly, in certain types of cancer,
SPARC is associated with highly aggressive tumor phenotypes,
whilst in others SPARC may function as a tumor suppressor.60 In
addition to extracellular mechanisms already mentioned, LOX also
regulates cancer progression within cells, here via actin polymeri-
zation promoting migratory phenotypes.61 Whereas LOX obtains
Cu from the secretory pathway (i.e., ATOX1–ATP7A), it is not known
how SPARC, MEMO1 and MEK1 are loaded with Cu.
II. RNA transcript levels of Cu-binding proteins in cancer
To derive if the assigned Cu-binding proteins are involved in cancer,
which subsequently may be used to elucidate new (druggable)
pathways, we used the TCGA data (http://cancergenome.nih.gov/)
to extract RNA transcript levels of the Cu proteome. Of the data
Fig. 1 Cellular localization of the 54 identified Cu-binding proteins. Subcellular localizations for 46 of the 54 copper-binding proteins are indicated
following the stringent criteria in Genecards.org with assignment by both UniProtKB and COMPARTMENTS (confidence levels 4 or 5). ATOX1, MEMO1, MT3,
LTF and S100A5 were localized according to the less stringent criteria with assignment by COMPARTMENTS (confidence level 4 or 5) only, and CUTA and
MT4 according to even less stringent criteria with assignment by COMPARTMENTS (confidence level 2). MOXD2P was the only Cu protein that remained
unassigned. As MOXD2P is a pseudogene of MOXD1, we speculated that it occupies the same subcellular site as MOXD1, i.e., the endoplasmic reticulum.
Colors indicate a protein’s function, with blue for the transporter; orange for the enzyme; and black for the protein with other or unknown function.
Paper Metallomics
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2016 Metallomics
for 25 diﬀerent cancers in TCGA, 18 contained information on
all the 54 Cu-binding proteins and, thus, these 18 cancer types
were used in the analysis. In each case, the RNA transcript level
in cancer tissues was compared to the RNA transcript level in
matching normal tissues. In Fig. 2, we show the resulting heat
map with log 2-fold changes for the 54 proteins (on the x axis)
in 18 cancer types (on the y axis) (red, upregulation; blue,
downregulation; and white, no change). In this plot, genes
placed close to each other on the y axis have more comparative
transcript levels than genes far away in the list, in the diﬀerent
cancer types.
Visual inspection revealed that many of the proteins in the
human Cu proteome are up- or downregulated in the diﬀerent
cancers in nontrivial patterns. For example, LOX, LOXL1-2,
SPARC and ENOX2 are upregulated, and S100B, PRNP, ENOX1,
SNCA, SOD3, HEPHL1 and AOC3 are downregulated in many
cancers (Z6 out of 18). With respect to ATOX1, it is upregulated
in breast, colorectal, uterus and liver tumors, but downregulated
in bile duct and pancreatic tumors (Fig. S1, ESI†).
III. Clustering of Cu-binding proteins
Next, building on the hierarchical clustering of the RNA expres-
sion data we divided the Cu-binding proteins on the y-axis, in
Fig. 2, into 8 clusters, with each cluster containing the genes
with the most similar expression patterns throughout the
diﬀerent cancers. Cluster 1 ranges from AOC1 to DBH, cluster
2 from MT4 to GPC1, cluster 3 from CUTA to AFP, cluster 4
from CP to ALB, cluster 5 from S100A5 to S100A13, cluster 6
from ENOX2 to SNCA, cluster 7 from LOX to TYR, and cluster 8
from LOXL1 to AOC3 (Fig. 2). Also the 18 tumor types can be
divided into 3 groups based on the hierarchical clustering
results. Group 1 contains thymus, head and neck, esophagus,
Fig. 2 Heat map of expression patterns for the human Cu proteome in cancers. Expression patterns of 54 copper-binding genes across 18 tumor types
are given. The color scale indicates the degree of change in expression (log 2-fold change), with blue for downregulation and red for upregulation. Genes
showing a log 2-fold change of at least 0.4 and a p-value below 0.05 were considered to be significant and are marked with an asterisk (*). Both the row
and column dendrograms indicate unsupervised hierarchical clustering of 54 copper-binding genes and 18 cancer types, respectively. The data were
classified using the Ward2’s hierarchical clustering method with a dissimilarity matrix based on the Pearson correlation as the distance metric.
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Fig. 3 Network analysis of the eight clusters of Cu-binding protein genes. Networks of interactions for each of the gene clusters (red, blue and black
circles) identified in the RNA expression heat map shown in Fig. 2. Red circles denote upregulation in breast cancer; blue circles, downregulation in breast
cancer; and black circles, no change in breast cancer. Each network shows the first-level partners (grey circles) in physical interactions (red connectors),
co-expression correlation (purple connectors) and genetic interactions (green connectors) for each gene in a cluster. The close proximity of the genes in
the network indicates a high level of interaction.
Paper Metallomics
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adrenal gland, bladder, and stomach cancers; group 2 contains
soft tissue, kidney, pancreas, bile duct and liver cancers; and
group 3 contains prostate, cervix, breast, uterus, thyroid, colorectal,
and lung cancers (Fig. 2).
To reveal the functional aspects of the eight clusters of
Cu-binding proteins derived from cancer expression patterns,
the clusters were analyzed with the GeneMANIA tool using the
Cytoscape software. This tool combines the available bio-
informatics information regarding the co-expression pattern,
and physical and genetic interactions of the genes within each
cluster, including here one extra level of interaction partners, to
derive what is known about functional relations between the
genes. Based on the distance between the gene representations
and the number of interactions between the genes within each
cluster plot, we detected that the genes in clusters 1, 3 and 8 are
closely related in terms of known functional parameters (many
interactions and short distances between the gene representa-
tions), whereas those in clusters 2 and 4 seem to be more
Fig. 4 Proteogenomic data for breast cancer subtypes. Heat map of correlations between protein (high-resolution accurate-mass tandem mass
spectrometry, MS/MS) and RNA-seq data for 36 Cu-binding proteins in breast cancer samples36 clustered according to the PAM50-defined subtypes
(labeled basal-like, HER2, luminal A and luminal B). Correlations between the protein and transcript levels were calculated using the Pearson correlation
coeﬃcient, r (from ref. 35). The genes were ordered according to r (shown in the left column) from high (top) to low (bottom) correlation. RNA/protein
abundance is depicted in a color scale from blue (low) to red (high) scaled within each row according to ref. 36.
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distant to each other with regard to known functions (few
interactions and genes spread apart). In addition, Cu-binding
proteins assigned to one cluster based on the heat map (blue/
red/black circles) sometimes appear as partner proteins (grey
circles) in other clusters (Fig. 3). This observation suggests that
the clusters have a high level of inter-connectivity.
IV. Exploration of breast cancer RNA transcript data
To further analyze the roles of the Cu-binding proteins, we
focused on the RNA transcript data for one cancer: breast cancer.
For the breast cancer TCGA data, we observed the upregulation
of F5, ATP7B and SLC31A1 in cluster 1, SCO2 and HEPHL1 in
cluster 2, CUTA, ATOX1, and COX17 in cluster 3, TYRP1 in
cluster 5, MT3 in cluster 7, and LOXL1-2, SPARC and MOXD1
in cluster 8 (red circles in Fig. 3). Because several Cu-binding
proteins are upregulated in breast cancer (corresponding to 26%
of the Cu proteome proteins), clearly, Cu-dependent processes
are of importance for breast cancer development. Moreover, we
found downregulated CUTC and AFP in cluster 3, S100B in
cluster 5, PRNP and SNCA in cluster 6, AOC2 and LOXL4 in
cluster 7, and PAM, SOD3 and AOC3 in cluster 8 in breast cancer
(blue circles in Fig. 3). One may imagine that even if cancer cells
have a higher demand for Cu than normal cells (which should
correlate with increased Cu uptake and/or decreased Cu export),
some Cu-binding proteins must likely be downregulated in order
to facilitate increased Cu loading of upregulated (and thereby,
cancer-promoting) Cu-binding proteins.
Of the upregulated Cu-binding proteins in breast cancer,
five were Cu transporters: SLC31A1, ATOX1, ATP7B, COX17 and
SCO2. This suggests that there is an increased Cu flow via
SLC31A1-mediated cell uptake followed by loading onto Cu-
dependent enzymes via the ATOX1–ATP7B path, and delivery of
Cu to mitochondria via COX17 and SCO2 in breast cancer.
Notably, the COX1 and COX2 genes, normally obtaining Cu via
COX17/COX11/SCO1/SCO2 were not upregulated in the breast
cancer data. This may hint at other purposes of increased Cu
delivery to mitochondria. For example, Cu import into mito-
chondria can regulate the mitochondrial redox status as rever-
sible changes in the redox state of cysteines in Cu-transport
proteins occur in parallel with Cu transfer.62,63 Five Cu-binding
enzymes were upregulated in breast cancer, namely, HEPHL1,
TYRP1, LOXL1, LOXL2, and MOXD1. Since ATP7B, but not
ATP7A, was upregulated in breast cancer, it appears that these
enzymes are loaded with Cu via ATP7B under these conditions.
The expression of the CUTA gene is also upregulated in breast
cancer and found in the same gene cluster as ATOX1 and COX17
(cluster 3). Since CUTA is predicted to be a mitochondrial
protein (Fig. 1), COX17 may be the chaperone that delivers Cu
to CUTA in mitochondria. However, in the functional network
analysis in Fig. 3, the nearest neighbors of CUTA are COMMD1
and SOD1, both of which are cytoplasmic proteins, posing the
question in which compartment is CUTA really present. Like
LOX1 and LOX2, SPARC is an extracellular protein upregulated
in breast cancer that is found in cluster 8. Therefore, we
speculate that SPARC, like LOX1 and LOX2, is loaded with Cu
via the secretory pathway, i.e., through the ATOX1–ATP7A/B
path, where ATP7B is the likely ATPase as is upregulated in
breast cancer.
To test these hypotheses, molecular studies investigating the
roles of COX17 and/or ATOX1 in providing Cu to CUTA, CUTA
localization, and the ATOX1–ATP7B path for loading Cu onto
SPARC are desired and, importantly, should be assessed as a
function of breast cancer molecular subtype. Similar analyses
of upregulated RNA transcripts of Cu-binding proteins in
each of the remaining 17 cancer types will likely result in a
number of unprecedented predictions of Cu-dependent processes
important in different cancer types.
V. ATOX1 protein upregulation in breast cancer tissues
We note that changes in RNA transcript levels not always reflect
the corresponding changes in protein levels as many Cu-binding
proteins may be regulated at the translational and/or post-
translational level. To address this possible caveat, we turned to
the recently-reported proteogenomics data36 on four PAM50-
defined intrinsic breast cancer subtypes (29 luminal A, 33 luminal
B, 18 HER2 (ERBB2)-enriched, and 25 basal-like) that contained
RNA and protein data for 36 of the here identified 54 Cu-binding
proteins. Analysis of the reported information revealed that 28 of
the 36 Cu-binding proteins (78%) have high-to-moderate positive
correlations between RNA transcript and protein levels (Fig. 4).
ATOX1 is one of the proteins with the highest positive correlation
(r = 0.67) indicating that if the RNA transcript level is up,
protein amount is up too. Thus, as a first approximation,
RNA data may be used as a measure of protein levels in this
set of genes. Nonetheless, proteomic studies are always desired
to support RNA transcript analysis because of the sensitivity
of high-resolution accurate-mass tandem mass spectrometry
(MS/MS) for determining protein levels.36
As a first step towards protein expression analysis, we
focused on ATOX1 because of its proposed transcription factor
role.26,27,64 Using immunohistochemistry we investigated the
amount and distribution of ATOX1 protein in 67 breast cancer
sections in tissue microarrays (TMAs). In agreement with the
RNA transcript data from TCGA (i.e., upregulation of ATOX1 in
breast cancer; Fig. 2), we found ATOX1 protein levels to appear
higher in cancerous than in normal breast tissues (examples
in Fig. 5 and Fig. S2, ESI†). This observation parallels the data
Fig. 5 Probing the ATOX1 protein in normal and breast cancer tissues. An
illustration of the IHC staining of ATOX1 protein in benign (A) and
cancerous (B) ductal breast tissue. Scale bars = 100 mm.
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from the Human Protein Atlas that report ATOX1 protein in
cancerous but not in normal breast tissues (http://www.protei
natlas.org; version 15, last accessed on 17 November 2016).
ATOX1 scoring data for the 67 breast cancer samples (consisting
of negative, weak andmoderate ATOX1 staining intensities) were
categorized into four molecular subtypes (i.e., luminal A, luminal
B, HER2, and triple negative) (Fig. 6). Inspection reveals that the
highest ATOX1 intensities were found in all cancer subtypes but
HER2 and, interestingly, the least proliferative subtype (luminal
A) was the one with the highest frequency of ATOX1 negatives. In
order to draw molecular conclusions, additional samples are
needed; more quantitative detection methods must be used (e.g.,
MS/MS, Western blot) and matching normal and cancer tissue
samples from the same patient are desired. With respect to
cellular distribution, ATOX1 was localized in both the cytoplasm and
the nucleus, with apparent increased nuclear localization in tissue
samples with the highest ATOX1 levels. This protein distribution
parallels the reported data from cell line studies and emphasizes the
prospect of ATOX1 activities in the nucleus.26,27,64 In future studies,
we will investigate the functional roles of ATOX1 in established
breast cancer cell lines (work in progress).
Conclusions
Our study brings together all known Cu-binding proteins into,
what we term, the Cu proteome, followed by extraction of their
expression levels in diﬀerent cancers using RNA transcript data
available in the TCGA database. The hierarchical clustering of
this data collection (shown as a heat map in Fig. 2) constitutes
an excellent resource for researchers aiming to test new hypotheses
around cancer progression. Cu is a necessary component of most
cancer cells,11,12 but the possible participation of Cu-binding
proteins in various steps of cancer is an underexplored topic.
For the breast cancer data, we performed an initial inspection of
Cu-binding proteins that are upregulated at the RNA transcript
level, and thereby we proposed mechanisms by which SPARC and
CUTA obtain Cu. We also compared the RNA transcript and
protein levels for most Cu-binding proteins as a function of
molecular subtypes of breast cancer (Fig. 4). Mechanistic studies
using a combination of animal, cell culture and biophysical
experiments are desired to test the hypotheses based on the
presented proteogenomic data.
As a top-down approach, we analyzed the expression patterns
of all human genes in cancer versus normal tissues from the
TCGA database using the ReviGO software and the GOseq tool,
Gorilla. This procedure condenses the extensive and complicated
information provided by expression patterns of individual genes
into an enrichment graph of biological attributes (GO terms)
that can be visualized (Fig. S3, ESI†). Notably, only a few over-
represented GO terms in the plot include Cu-binding proteins.
AOC3, MEMO1, LTF and SPARC are the four Cu-binding proteins
found in the plot, and they are connected to the following
enriched GO terms: response to metal ion (AOC3), cell division
(SPARC), ERBB2–ERBB3 signaling (MEMO1), regeneration (AOC3),
catabolism (AOC3) and regulation of cell proliferation (LTF).
Fig. 6 ATOX1 expression in breast cancer tissue of diﬀerent molecular subtypes. (A) Legend for the manual scoring of ATOX1 expression levels
(i.e., staining intensity) in microarrays of breast cancer tissue sections. (B) Scoring results for ATOX1 expression levels in cancerous breast tissues
(67 samples) of the following molecular subtypes: triple negative (TNBC), HER2, luminal A, and luminal B.
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With more studies assessing the roles of Cu-binding proteins in
cancer, the database of information will expand, and we predict
that GO terms related to Cu-dependence will become of
increased significance in the future.
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